ASH 2020 | Cobimetinib-based treatment for R/R multiple myeloma
Marc Raab, MD, German Cancer Research Center, Heidelberg, Germany, shares the details of a Phase Ib/II study (NCT03312530) of the MEK inhibitor cobimetinib (C) to treat relapsed/refractory (R/R) multiple myeloma as a single agent or combined with venetoclax (V) and atezolizumab (A). Cobimetinib was theorized to be more efficacious in combination with BCL-2 inhibition and PD-L1 inhibition due to a shift in apoptotic balance towards death and an improved anti-tumor immune response. Patients were randomized across three arms: C, C+V, or C+V+A and responses and pharmacokinetics were analyzed. The results found that responses were significantly higher in the two combination treatment groups for t(11;14) positive patients compared to non-t(11;14). Since efficacy was poor in the single agent arm and addition of A to C+V did not significantly improve outcomes, further investigation will continue into C+V treatment for t(11;14) positive patients. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Prof. Marc Raab, MD, has received research funding from Amgen, Sanofi, Heidelberg Pharma and Celgene; and has been a member of a board of directors or advisory committee for Amgen, Sanofi, Heidelberg Pharma, Novaritis, Celgene, Janssen, Bristol-Myers Squibb and Takeda.
